Most Active SPACs

Couples would have to live with parents for over 3 years to save for a house deposit

Couples that move in with their parents to save on rent would need to live in their family home for 37 months in order to save a 10% deposit of £26,700.

Slam Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing April 15, 2021

Slam Corp. (NASDAQ: SLAMU) (the "Company") announced that, commencing April 15, 2021, holders of the units sold in the Company's initial public offering of 57,500,000 units, completed on February 25, 2021, may elect to separately trade the Class A ordinary shares and warrants included in the units. Those units not separated will continue to trade on the Nasdaq Stock Market LLC ("NASDAQ") under the symbol "SLAMU," and the Class A ordinary shares and warrants that are separated will trade on the NASDAQ under the symbols "SLAM" and "SLAMW," respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants.

• 
  New Residential Investment Corp. Announces Pricing of Public Offering of Common Stock

  Business Wire
• Coinbase Announces Update Regarding Conversion of Shares of Class B Common Stock to Shares of Class A Common Stock

  Business Wire

Cancer Biotech Tango Therapeutics Picks Boxer Capital's SPAC To Go Public Via $353M Merger

The latest biotech-SPAC deal has arrived with Cambridge, Massachusetts-based Tango Therapeutics announcing its reverse merger with Boxer Capital’s blank-check company BCTG Acquisition Corp (NASDAQ: BCTG). With a spotlight on three lead programs, Tango expects total proceeds of $353 million in the deal, including around $167 million held in the SPAC and an additional $186 million in PIPE financing. When the deal closes, Tango’s stock is expected to list on the NASDAQ under the stock symbol “TNGX.” Tango develops drugs based on synthetic lethality, a concept that involves tapping into a genetic vulnerability in cancer. Its focus is on developing drugs that counteract the loss of tumor suppressor genes and reverse cancer cells’ ability to evade the immune system. Lead program TNG908 is designed to block PRMT5, an enzyme expressed at high levels in tumors and whose synthetic lethal pair is a gene called MTAP. The company plans to file FDA investigational new drug (IND) application by the end of this year. A second IND filing is planned for next year for an inhibitor of a cancer protein called USP1, which Tango intends to develop for BRCA1-mutant breast, ovarian, and prostate cancers. The third program for an undisclosed target is expected to reach the clinic in 2023 for lung cancer characterized by a mutation to the STK11 gene. The company also plans to continue work on preclinical compounds in its pipeline to file a new IND every 12 to 18 months. In 2018, Tango signed Gilead Sciences Inc (NASDAQ: GILD) to work together on five drug targets. Last year the companies expanded the pact to encompass 15 targets, which excludes Tango’s three lead candidates. Tango and BCTG have scheduled a conference call today at 10 a.m. E.T. Price Action: BCTG shares are up 5.26% at $11.80 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaaTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

• 
  Grab, the food-delivery giant backed by SoftBank, is going public in the US via the largest-ever SPAC merger, valuing it at $40 billion

  Business Insider
• 
  Singapore-based Grab going public in largest-ever SPAC deal

  Axios